Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension

Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension

European Respiratory Journal – June 2022

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study